The role of tumor vascularisation in benign and malignant cardiovascular neoplasms: A comparison of cardiac myxoma and sarcomas of the pulmonary artery

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 309-318

  Gaumann, Andreas ^a   Strubel, Gerson ^a   Bode Lesniewska, Beata ^b   Schmidtmann, Irene ^c   Kriegsmann, Jörg ^d   Kirkpatrick, C James ^c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d Centre for Histology Cytology and Molecular Diagnostics   (Germany)

Author keywords

Angiogenesis; Morphometry; Myxoma; Sarcoma; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; LIGAND; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER MORPHOLOGY; CAPILLARY DENSITY; CARCINOGENESIS; CELL INFILTRATION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART MYXOMA; HEART SARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ARTERY SARCOMA; MACROPHAGE; MALE; MALIGNANT NEOPLASTIC DISEASE; MORPHOMETRICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ADULT; AGED; ALKALINE PHOSPHATASE; ANOXIA; FEMALE; HEART NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MYXOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PULMONARY ARTERY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SARCOMA; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR NEOPLASMS;

EID: 48749086611     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000008     Document Type: Article

References (25)

1. Amano J, Kono T, Wada Y, et al: Cardiac myxoma: its origin and tumor characteristics. Ann Thorac Cardiovasc Surg 9: 215-221, 2003.
2. Shapiro LM: Cardiac tumours: diagnosis and management. Heart 85: 218-222, 2001.
3. Pucci A, Gagliardotto P, Zanini C, et al: Histopathologic and clinical characterization of cardiac myxoma: review of 53 cases from a single institution. Am Heart J 140: 134-138, 2000.
4. Burke AP and Virmani R: Sarcomas of the great vessels. A clinicopathologic study. Cancer 71: 1761-1773, 1993.
5. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
6. Laakkonen P, Waltari M, Holopainen T, et al: Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 67: 593-599, 2007.
7. Matsumoto T and Claesson-Welsh L: VEGF receptor signal transduction. Sci STKE 2001: RE21, 2001.
8. Bergers G, Song S, Meyer-Morse N, Bergsland E and Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295, 2003.
9. Vermeulen PB, Gasparini G, Fox SB, et al: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38: 1564-1579, 2002.
10. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69: S4-S10, 2005.
11. Kono T, Koide N, Hama Y, et al: Expression of vascular endothelial growth factor and angiogenesis in cardiac myxoma: a study of fifteen patients. J Thorac Cardiovasc Surg 119: 101-107, 2000.
12. Sakamoto H, Sakamaki T, Kanda T, et al: Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells. Circ J 68: 488-493, 2004.
13. Salvesen HB and Akslen LA: Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 84: 538-543, 1999.
14. Ohta M, Kitadai Y, Tanaka S, et al: Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 22: 773-778, 2003.
15. Dankbar B, Padro T, Leo R, et al: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636, 2000.
16. Zhang T, Koide N, Wada Y, et al: Significance of monocyte chemotactic protein-1 and thymidine phosphorylase in angiogenesis of human cardiac myxoma. Circ J 67: 54-60, 2003.
17. Ramanathan M, Pinhal-Enfield G, Hao I and Leibovich SJ: Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol Biol Cell 18: 14-23, 2007.
18. Hlatky L, Hahnfeldt P and Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893, 2002.
19. Chou CY, Huang SC, Tsai YC, Hsu KF and Huang KE: Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma. Gynecol Oncol 65: 225-231, 1997.
20. Hata K, Hata T, Iida K and Miyazaki K: Expression of thymidine phosphorylase in uterine sarcoma and uterine leiomyoma: association with microvessel density and Doppler blood flow analysis. Ultrasound Obstet Gynecol 10: 54-58, 1997.
21. Yudoh K, Kanamori M, Ohmori K, et al: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84: 1610-1615, 2001.
22. Emoto M, Iwasaki H, Ishiguro M, et al: Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 30: 1232-1241, 1999.
23. West CC, Brown NJ, Mangham DC, Grimer RJ and Reed MW: Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur J Surg Oncol 31: 1198-1205, 2005.
24. Dias S, Hattori K, Heissig B, et al: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 98: 10857-10862, 2001.
25. Sjoblom T, Shimizu A, O'Brien KP, et al: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783, 2001.